Home > Oncology > ESMO 2020 > Gynaecological Cancers > Treatment of recurrent ovarian cancer

Treatment of recurrent ovarian cancer

ESMO 2020
Individual dosing of PARP inhibitor niraparib is associated with less adverse events, results from the NORA study showed. NINJA and INOVATYON demonstrated that neither nivolumab monotherapy nor trabectedin improve survival in patients with recurrent ovarian cancer. In patients with platinum-sensitive recurrent ovarian cancer, the PARP inhibitor niraparib demonstrated a significant benefit in progression-free survival (PFS) compared with placebo, regardless of the presence or absence of BRCA mutations or HRD status [1]. The starting dose in this trial was 300 mg daily. However, a retrospective analysis indicated that an individualised starting dose based on baseline body weight and platelet count may improve the safety profile without compromising efficacy [2]. Therefore, in the phase 3 NORA trial, patients in the niraparib arm received an individualised starting dose of niraparib [3]. The study enrolled 265 patients; 88 were allocated to re...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on